Crestor Overdose and Accidental Excess Dose: What to Do and What to Expect

Rosuvastatin, sold under the brand name Crestor, is an oral HMG-CoA reductase inhibitor (a statin) approved by the FDA for lowering LDL cholesterol and reducing cardiovascular risk. This article covers what happens after a patient takes more rosuvastatin than prescribed, whether by accident (a duplicate dose, a dispensing error) or in larger amounts.

A single accidental double-dose of rosuvastatin (for example, taking 40 mg instead of 20 mg) does not require emergency treatment in most healthy adults. There is no specific antidote for rosuvastatin overdose. The two toxicities that matter are dose-dependent muscle injury (rhabdomyolysis) and liver enzyme elevation, both of which are detectable with blood tests and typically resolve with observation. According to prescribing information, clinical trials of rosuvastatin at doses up to 80 mg did not identify a specific overdose syndrome requiring specialized treatment beyond supportive care. This does not mean large or repeated overdoses are risk-free, and anyone uncertain about the amount taken should call Poison Control at 1-800-222-1222.

How rosuvastatin works, and why that matters for overdose

Rosuvastatin works by blocking HMG-CoA reductase, which controls the rate of cholesterol production in the liver. When cells have less cholesterol available, they respond by making more LDL receptors on their surface, which draws additional LDL cholesterol from the bloodstream. At typical treatment doses, rosuvastatin's mechanism of action is well understood and directly underlies its heart and stroke benefits, as confirmed in major clinical trials including JUPITER, which studied patients with raised inflammatory markers and found that rosuvastatin substantially lowered the rate of major cardiovascular events compared to placebo. The precise size of this benefit represents a specific finding from that trial, which a healthcare provider or the trial's original report should verify before discussing with a patient; however, the overall finding that rosuvastatin reduces cardiovascular events is solidly supported across statin research.

The same enzyme inhibition that lowers cholesterol can, at higher plasma concentrations, stress skeletal muscle and liver cells. Rosuvastatin has relatively low oral bioavailability, and the FDA label describes hepatic metabolism and biliary excretion as the primary elimination routes, with a terminal half-life of roughly 19 hours. That half-life is the basis for the monitoring windows below.

What counts as an overdose, and what does not

A single accidental double-dose is not the same clinical event as sustained overuse. The FDA label states that no specific overdose treatment exists and that overdose has not produced a distinct toxic syndrome in the doses studied during drug development, up to 80 mg. That is reassuring for an isolated mistake, but 80 mg is twice the approved ceiling and is not a target to aim for; the 40 mg maximum exists because higher doses increase myopathy and proteinuria without a proportional increase in cholesterol lowering.

Some patients are at higher risk from a given dose because of how their body handles the drug rather than the number of milligrams they took:

• Patients of East Asian ancestry have higher plasma concentrations at a given dose, which is why FDA labeling recommends starting at 5 mg in this population rather than the usual starting dose.
• Patients with significant kidney impairment accumulate rosuvastatin and are capped at lower maximum doses.
• Patients on interacting medications (below) can reach overdose-level exposure while taking their normal prescribed dose.

Signs of rosuvastatin toxicity

Most overdoses, including intentional larger ingestions, are clinically silent for the first day. When toxicity develops, it centers on muscle and liver.

Muscle injury ranges from mild aching to rhabdomyolysis. Warning signs include diffuse muscle pain (often the thighs and calves), weakness, and dark or cola-colored urine, with CK elevations well above the normal range on lab testing. Statin-associated rhabdomyolysis is uncommon at therapeutic doses but is a recognized, dose-related risk that has been described in case reports and pharmacovigilance analyses; the exact relative frequency compared with other statins varies across published analyses and should not be quoted as a precise number without checking the specific study.

Liver enzyme elevation is usually asymptomatic and detected only on blood work. The FDA label describes persistent transaminase elevations above three times the upper limit of normal as an uncommon event at therapeutic doses. In overdose, hepatocellular stress is dose-related and generally reversible once the drug is stopped or reduced. Jaundice or coagulopathy would suggest more severe liver involvement and warrants urgent evaluation, but this pattern is not typical of isolated statin overdose.

Proteinuria has been reported more often with rosuvastatin than with some other statins at higher doses, believed to reflect reduced tubular reabsorption of protein rather than glomerular damage; it typically resolves when the dose is lowered.

What to do immediately after an accidental excess dose

Rosuvastatin overdose decision framework

If significant overdose is suspected, reasonable baseline labs include creatine kinase (repeated at 24 hours), a comprehensive metabolic panel with ALT/AST, and urinalysis to check for myoglobin. These are standard supportive-care measures rather than a specific antidote protocol, because no such antidote exists for rosuvastatin.

Why hemodialysis is not expected to help

Rosuvastatin is highly bound to plasma proteins, which limits how much free drug is available for a dialysis membrane to remove, and the FDA label describes a large volume of distribution consistent with substantial tissue uptake. In practical terms, this means clinicians rely on supportive care and the body's own hepatic clearance rather than dialysis to manage a rosuvastatin overdose. This differs from overdoses involving water-soluble drugs with low protein binding, where dialysis can meaningfully shorten exposure.

Drug interactions that turn a normal dose into an effective overdose

A dose within the labeled range can produce overdose-level blood concentrations when combined with a drug that raises rosuvastatin exposure. This is arguably the more common real-world path to toxicity, compared with a one-time accidental double-dose.

• Cyclosporine substantially raises rosuvastatin exposure, and the FDA label describes this combination as one to avoid or manage with dose limits; verify the exact recommended cap with current labeling before advising a specific patient.
• Gemfibrozil increases rosuvastatin exposure and independently raises myopathy risk through a separate metabolic mechanism. Guideline bodies covering statin-associated muscle symptoms recommend avoiding this combination where possible.
• HIV protease inhibitors (such as atazanavir/ritonavir or lopinavir/ritonavir) raise rosuvastatin exposure through transporter inhibition; the FDA label specifies a lower maximum dose for patients on these regimens.

When a patient on a stable, labeled rosuvastatin dose develops unexplained muscle symptoms, reviewing the full medication list for a new interacting drug is a reasonable first step, before assuming the statin dose itself is the problem.

Typical recovery timeline

Based on the roughly 19-hour half-life described in FDA labeling, most of a single large dose clears within three to four days (four to five half-lives). A commonly used, generic monitoring approach looks like this:

• First 6 hours: baseline labs if a significant overdose is suspected; symptoms are unlikely this early.
• 6 to 24 hours: repeat CK if any muscle symptoms appear.
• 24 to 72 hours: the period during which statin-related muscle injury, if it is going to occur, most often becomes apparent.
• 72 hours to 7 days: recheck liver enzymes; most transaminase elevations from an isolated overdose resolve in this window.

A retrospective poison-center case series describing outcomes after statin-related calls has been cited in prior versions of this material; because the primary source could not be verified for this revision, the specific figures from that series are not reproduced here. The general pattern reported in the toxicology literature, and consistent with the pharmacology above, is that isolated statin overdoses are usually managed with observation rather than intensive intervention, but a reader should not rely on an unverified statistic to decide against seeking care.

Chronic supratherapeutic dosing is a different, higher-risk problem

Sustained overuse, for example weeks of a dispensing error providing a higher-strength tablet than prescribed, is not equivalent to a one-time accidental double-dose. Sustained higher exposure allows longer enzyme inhibition in muscle tissue, which raises the chance that myopathy progresses toward rhabdomyolysis. Case reports of pharmacy dosing errors have described marked CK elevation and, in at least one instance, a need for IV fluids for early rhabdomyolysis, with recovery after the correct dose was restored. Anyone who suspects their dispensed tablets do not match their prescription, including a change in pill appearance at refill, should confirm the dose with their pharmacy before taking the next tablet.

Restarting rosuvastatin after an overdose event

There is no single validated protocol for every scenario, and this decision should be made with the prescribing clinician rather than by the patient alone. As general principles reflected in statin-safety literature and label guidance:

• If CK stayed only mildly elevated and the patient was never symptomatic, restarting at the previously prescribed dose once labs have normalized is a reasonable approach, without a mandatory washout period.
• If CK rose markedly or rhabdomyolysis occurred, a washout period followed by rechallenge at the lowest available dose, with repeat CK monitoring, is a more cautious approach used in clinical practice.
• If significant liver enzyme elevation occurred, switching to a statin that undergoes minimal hepatic CYP metabolism (such as pravastatin or pitavastatin) is an option some clinicians consider rather than rechallenging with rosuvastatin.

For most patients taking rosuvastatin for established cardiovascular disease, the long-term benefit of continued statin therapy generally outweighs the risk of a carefully managed rechallenge at a reduced dose, but this is an individualized decision that depends on the severity of the overdose event and the patient's cardiovascular risk.

What is established, what is plausible, and what is not established

Established: Rosuvastatin has no specific overdose antidote. A single accidental double-dose is generally low-risk in adults without kidney or liver disease. Muscle injury and liver enzyme elevation are the recognized dose-related toxicities. Hemodialysis is not an effective way to remove the drug, based on its protein binding described in FDA labeling. Interacting drugs (cyclosporine, gemfibrozil, certain HIV protease inhibitors) can raise rosuvastatin exposure well above what the prescribed dose alone would produce.

Plausible but not rigorously quantified for this article: The exact relative risk of rhabdomyolysis with rosuvastatin compared with other statins, the precise percentage of overdose calls that require no treatment, and the exact success rate of rechallenge after a myotoxic event. These figures appear in the statin literature but the specific studies behind them require direct verification before being cited as precise numbers.

Not established: That any home remedy, supplement, or over-the-counter treatment reduces the risk of muscle or liver injury after a rosuvastatin overdose. That activated charcoal has controlled trial evidence specifically in statin overdose; its use is a general toxicology judgment call, not a statin-specific proven intervention.

When to seek care versus when to watch and wait

Call Poison Control (1-800-222-1222) for any overdose beyond a single accidental extra dose, for any symptomatic patient, and for any pediatric ingestion regardless of amount. Go to an emergency department for muscle pain with dark urine, vomiting, drowsiness, confusion, or a known large or intentional ingestion. Home observation with a plan to skip the next dose is reasonable only for an isolated, small, accidental double-dose in an otherwise healthy adult with no new symptoms.